SCHEMBL4612709

SCHEMBL4612709

OCCSc1cc[c]cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA7 P43166 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
ALDH1A1 P00352 4/20 0.39
MAPK1 P28482 2/20 0.39
S100A4 P26447 3/20 0.36
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CDC25A P30304 2/20 0.36
CDC25B P30305 2/20 0.36
APAF1 O14727 1/20 0.36
MAP2K7 O14733 1/20 0.36
NPC1 O15118 1/20 0.36
GMNN O75496 1/20 0.36
TDP2 O95551 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010463 0.86 CA2 (0.50) CA2CA12CA1CA7CA13
SCHEMBL6276055 0.85 CA2 (0.51) CA2CA12CA1CA7CA13
SCHEMBL8637757 0.82 CA2 (0.61) CA2CA12CA1CA7CA13
SCHEMBL11281750 0.80
SCHEMBL4612773 0.76 ALDH1A1 (0.39) CA2CA12CA1CA7CA13
SCHEMBL5467678 0.76 ALDH1A1 (0.39) ALDH1A1MAPK1
SCHEMBL2879670 0.76 CA12 (0.47) CA2CA12CA1CA7CA13
SCHEMBL4613527 0.76 ALDH1A1 (0.39) ALDH1A1MAPK1
SCHEMBL9007909 0.76 ALDH1A1 (0.34) ALDH1A1MAPK1
SCHEMBL95988 0.75 ALDH1A1 (0.70) CA2CA12CA1CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371747-B2 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA & CO. (CA) 2008-05-13 US claimed
EP-1446115-B1 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP claimed
EP-1446115-A4 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-02-02 EP claimed
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA LTD. (CA) 2005-01-20 US claimed
EP-1446115-A2 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS Merck Frosst Canada & Co. (CA) 2004-08-18 EP claimed
WO-2003041649-A2 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-05-22 WO claimed
EP-0229370-B1 GUANIDINOBENZOIC ESTER DERIVATIVE, A PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Eisai Co., Ltd. (JP) 1989-04-19 EP claimed
EP-0088050-B1 COLOURED PHOTO-HARDENABLE COMPOSITION CIBA-GEIGY AG (CH) 1986-09-03 EP claimed
US-4582862-A QUICK-SETTING PRINTING INKS BASED ON ACRYLATED RESINS CIBA-GEIGY CORPORATION (US) 1986-04-15 US claimed
EP-0088050-A2 Coloured photo-hardenable composition CIBA-GEIGY AG (CH) 1983-09-07 EP claimed
CN-114641388-A Water-washable composition for use in 3D printing 巴斯夫欧洲公司 2022-06-17 CN disclosed
US-7371747-B2 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA & CO. (CA) 2008-05-13 US disclosed
EP-1446115-B1 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP disclosed
EP-1446115-A4 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-02-02 EP disclosed
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA LTD. (CA) 2005-01-20 US disclosed
EP-0097124-A2 Process for the photopolymerisation of unsaturated compounds CIBA-GEIGY AG (CH) 1983-12-28 EP disclosed
US-4305891-A PHOSPHORYLATION, DEESTERIFICATION COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 1981-12-15 US disclosed
US-4303652-A Fiber-reactive phosphorus mothproofing agents COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 1981-12-01 US disclosed
US-4056544-A Anthraquinone compounds BAYER AKTIENGESELLSCHAFT (DT) 1977-11-01 US disclosed
US-3956345-A POLYESTER CIBA-GEIGY AG (CH) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors CTSB, CTSK, CTSS CA2 858/4885CA12 1835/4885CA1 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.